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that compares a pair of GWAS for similarity among the top SNP associations, top genes identiﬁed, gene functional
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six complex genetic disorders at the SNP-level, gene-level, gene-cluster-level, andpathway-level.Wemake concrete
hypotheses regarding novel pathway associations for several complex disorders considered, based on the results of
Joint GWASAnalysis. Together, these results demonstrate that common complex disorders share substantiallymore
genomic architecture than has been previously realized and that themeta-analysis of GWAS needs not be limited to
GWAS of the same phenotype to be informative.
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Genome Wide Association Studies (GWAS) have resulted in many
replicated single nucleotide polymorphisms (SNPs) that show modest
effects on everything from human height [22] and body mass index
[42] to cancer metastasis [11] and drug efﬁcacy [8]. However, most
GWAS identify only a handful of SNPs thatmeetmultiple testing correc-
tion criteria for statistical signiﬁcance, and the desire to mine additional
biological data from GWAS has resulted in various adjunct statistical
methods including 1) enrichment of biological pathways, termed “path-
way analysis” [41] and 2) combination of multiple GWAS of the same
phenotype, or GWAS meta-analysis [10,46]. We suggest here a method
we call Joint GWAS Analysis that is a combination of pathway- and
meta-analysis, but one that is not limited to the analysis of GWAS of
the same trait or disease. Instead, we leverage widespread pleiotropy
of complex disease [35] to gain increased biological insight by compar-
ing potentially unrelated GWAS. This is a method that can be under-
stood as an alternative or as a complementary approach to a standard
meta-analysis..edu (M.J. McGeachie).
. This is an open access article underA small portion of the top SNPs in a GWAS are usually prioritized for
further study or replication in additional populations [36], typically
those SNPs reaching p b 5 ∗ 10^ − 8. This is a conservative strategy
designed to minimize false-positive associations, while missing many
true-positive associations that do not meet statistical signiﬁcance. In
contrast, pathway analysis methods are a companion to GWAS studies
that consider much larger proportions of the top SNPs and investigate
their aggregate associations to known biological groupings ormetabolic
pathways [12]. Pathway analysis studies have been successful in identi-
fying additional biological insight and ﬁnding groupings of genes that
represent biological disease processes [28]. These kinds of approaches
have shown the value in considering many more of the top GWAS
SNPs, even though those hits are more likely to include false-positive
associations.
At the same time, the modern picture of the genetic architecture of
common complex disorders has become much more broad-based than
traditionally supposed [36], with most disorders and complex traits
thought to have many variants of small effect [40,43]. A study of the
entire NHGRI GWAS catalog [16], which archives all SNP-phenotype
associations from GWAS reported in the literature, identiﬁed 16% of
genes and 4.6% of GWAS SNPs to be associated with more than one
cataloged condition or trait [33]. Furthermore, these variants are
increasingly realized to be shared across similar conditions and traits,
including: height and body mass index [15]; cognitive and learningthe CC BY-NC-SA license (http://creativecommons.org/licenses/by-nc-sa/3.0/).
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diseases [13]. Genes have been shown to affect disparate phenotypes
as well, including prostate cancer and type 2 diabetes [14], and more
general studies of human gene pleiotropyhave shownqualitative differ-
ences between pleiotropic genes that inﬂuence related and unrelated
traits [6].
We propose that any time two diseases may have common biologi-
cal causes or etiology, comparing the GWAS of the two diseases may
lead to greater understanding of either disease than was possible in
separate analyses. In this study we explore the comparison of two
GWAS of similar and of disparate phenotypes. Our hypothesis is that
by comparing the GWAS of two complex genetic diseases, those vari-
ants that exhibit moderate evidence of association with both disease
phenotypes are more likely to represent genomic loci truly associated
with each of the diseases, and thus provide an important source of addi-
tional biological insight. We show that this comparison does lead to
novel biological pathways associated with disease phenotypes, and
furthermore that the two complex disorders need not be commonly
considered to have a clinical relationship to have common genetic risk
factors. Ourmethod, Joint GWASAnalysis, is based upon the enrichment
of top SNPs in a pair of GWAS. We show that this method identiﬁes
increasingly more information biologically related to the phenotypes as
one transitions from small-scale genomic resolution at SNPs, to genes,
to gene groups, and ﬁnally to the large-scale resolution of biological
pathways.
We demonstrate this using six published GWAS from the Welcome
Trust Case Control Consortium (WTCCC), on six different diseases that
have varying degrees of etiological similarity. We consider the genome-
wide SNP data from WTCCC on different populations of 2000 patients
with one of bipolar disorder (BP), coronary artery disease (CAD), Crohn's
disease (CD), rheumatoid arthritis (RA), type 1 diabetes (T1D), type 2
diabetes (T2D); and 3000 common controls. We then conduct pair-
wise comparisons of these six GWAS, at the SNP-level, the gene-level,
gene-cluster level, and the pathway-level. We show that Joint GWAS
Analysis results in increased biological insight at the pathway level for
several pairs of the WTCCC diseases, above what is identiﬁable from a
similar pathway analysis of a single GWAS.Methods
GWAS methods
We obtained genome-wide SNP data from the Welcome Trust Con-
sortium on six different cohorts for six common complex disorders (BP,
CAD, CD, RA, T1D, and T2D) and a control cohort, all genotyped on
the 500 k Affymetrix gene chip (Affymetrix). More information on the
genotyping and inclusion criteria are available from theWTCCC publica-
tions (2007). We performed simple case–control GWAS on each of the
six WTCCC diseases by comparing each of the disease populations
(n = 2000) to the common control group (n = 3000). We followed
advice from the original WTCCC GWAS publication [1] on how to ﬁl-
ter for spurious SNP associations and control for genomic stratiﬁcation,
performing our GWAS after removing SNPs with Hardy–Weinberg Equi-
librium (HWE) probability test scores lower than b0.001, minor allele
frequency b0.05, missingness N0.001, and individuals more than four
standard deviations from the mean on any of the top six genotype
principal components; and obtained similar results as the original
authors. We then selected from each GWAS a common panel of
~100,000 tag-SNPs that were in less than r2 = 0.3 linkage disequilib-
rium. GWAS, ﬁltering, and linkage-disequilibrium pruning were
performed using PLINK [26]. Outliers with extremely low P values
in each GWAS were removed by checking for nearby SNPs with sim-
ilar p-values; this accomplished outlier removal similar to that
described by WTCCC (2007) to remove spurious associations driven
by genotyping errors.Joint GWAS SNP list selection
For each pair of GWAS, we considered a “Joint GWAS” where one
disease in the pair is the “Target Disease” and the other is the “Cross
Disease” (and similarly, we refer to “Target GWAS” and “Cross GWAS”).
A glossary of terms deﬁned appears at the end of this work. We
constructed a “Joint GWAS SNP list" of SNPs for each pair of GWAS by
performing the following protocol (see also Fig. 1).
1) We sorted the SNPs of both GWAS by their statistical association to
their own phenotype in decreasing order of signiﬁcance.
2) We considered an increasing subset of the topMSNPs.We started by
considering the top M = 1 SNPs, and increased M by one until M
reached the total number of tag SNPs.
3) At each size M, we identiﬁed the set of “Common SNPs” that was
present in the top M SNPS of both Target and Cross GWAS. We
obtained p-values for the enrichment of Common SNPs for each
value of M from the hypergeometric distribution.
4) The sizeM such that the hypergeometric p-value is a minimum over
all window-sizes was chosen as the SNP rank cutoff value.
5) The Joint GWAS SNP list is the set of Common SNPs whenM is equal
to the SNP rank cutoff value. The Joint GWAS SNP list of length Nsnp.
We used Joint GWAS SNP lists constructed this way in the rest of the
study. Fig. 1 shows a schematic of the dataﬂow and study design used in
this work, starting with the enrichment of paired GWAS SNPs and the
creation of the Joint GWAS SNP list, and following the Joint GWAS SNP
list all the way to the pathway level.SNP comparison methods
To make a comparison that demonstrates the difference between
the Joint GWAS method and standard GWAS pathway analysis
methods, we made a list of “Target GWAS SNPs” for the Target Disease.
This was composed of the top Nsnp SNPs from the Target GWAS, where
Nsnp was the size of the Joint GWAS SNP list. We used the NHGRI GWAS
catalog [16] as a reference of known disease SNPs discovered by GWAS.
SNPs listed in the catalog for any GWAS of the Target Disease were
selected to form a reference “NHGRI Disease SNP list" for the Target
Disease.
SNPs in the Joint GWAS or Target GWAS SNP listswere considered to
match SNPs in the NHGRI Disease SNP list if they were within a linkage
disequilibrium tolerance of r2 = 0.3.We computed SNP LD distances by
using a cohort of Caucasians imputed to 1000-Genomes [2], comprising
over six million imputed SNPs. Using this reference group, we checked
the linkage disequilibrium between SNPs using PLINK.Gene comparison methods
We translated the Joint GWAS SNP list to an associated “Joint GWAS
gene list” by using the UCSC Genome Browser (build HG18, which cor-
responds to the genotyping done byWTCCC on the six GWAS). In cases
where one SNP mapped to multiple genes, we included all genes. As
with our comparison at the SNP level, we made a list of the Target
GWAS genes to serve as a point of comparison. This “Target GWAS
gene list” was composed of the top Ng genes of the Target GWAS,
where Ng is the size of the Joint GWAS genes list, and the genes are
ordered by the p-value of the SNP within the gene that has the lowest
p-value for association with the Target Disease.
We used the genes reported in the NHGRI catalog for all GWAS
ﬁtting the Target Disease as the reference for comparison. Matching
between genes in the Joint GWAS gene list or the Target GWAS gene
list to the NHGRI Disease gene list was performed by checking the lists
for the same gene names.
Fig. 1. Schematic of Joint GWASAnalysis. In Joint GWASAnalysis, twoGWASof different diseases are compared for enrichment of top SNPhits. CommonSNPs occurring prior to the point of
maximum enrichment become the “Joint GWAS SNPs.” These SNPs are then mapped to genes to make the Joint GWAS gene list. From these genes, enriched pathways are computed.
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Weused the DAVID (Database for Annotation, Visualization and Inte-
grated Discovery) pathway enrichment online tool [19] to obtain func-
tional clusters for the genes in the Joint GWAS, Target GWAS, and
NHGRI Disease gene lists. In order to use DAVID's web services interface,
we ﬁrst translated the gene list from canonical gene names to mRNA
reference keys, which we did using a mapping from the UCSC Genome
Browser [23]. This resulted in between 84.0% and 89.5% of the genes in
each list being successfully mapped and identiﬁed by DAVID. We then
obtained gene functional clusters from DAVID, allowing the Target
GWAS gene list to cluster with genes from the NHGRI list and allowing
the Joint GWAS gene list to cluster with genes from the NHGRI list. We
deﬁned the number of NHGRI Disease genes matched by the Joint
GWAS gene list to be the number of NHGRI Disease genes in clusters
with at least one gene from the Joint GWAS gene list; we deﬁned the
number of NHGRI genes matched by the Target GWAS gene list in a
similar way. We deﬁned any gene from the Joint GWAS gene list that
was mapped to a gene cluster including at least one NHGRI Disease
gene as a true-positive gene association for the Target Disease. We then
computed false positive rates for the Joint GWAS gene list by comparing
the number of true-positive gene associations to the size of that list
(Table S3). We similarly computed the false-positive rate for the Target
GWAS gene list (Table S3).
Pathway cluster methods
We used DAVID to generate enriched pathways of genes from the
Joint GWAS gene list and Target GWAS gene lists for each pair of
diseases. We used the default settings on DAVID for all DAVID opera-
tions, and discarded pathways with signiﬁcance levels greater than
0.05 and pathway clusters with enrichment scores less than 1.0. We
used the NHGRI Disease gene list to obtain enriched pathway clusters
using DAVID, that we termed “NHGRI Disease pathways clusters”
for the Target Disease. Pathway clusters are groups of overlappingpathways that may be very redundant if considered separately. The
genes in the pathways in a single pathway cluster tend to overlap to a
large extent; thus, for each pathway cluster, we counted the number of
genes from the Joint GWAS gene list (or Target GWAS gene list) partici-
pating in one of their own enriched pathways, and that are alsomembers
of the NHGRI Disease pathway cluster in question. We compared these
two numbers using Chi-square or Fisher's exact tests, and if there is a
signiﬁcant difference we called this cluster signiﬁcantly “covered” for
either the Joint GWAS gene list or the Target GWAS gene list. The num-
bers of signiﬁcantly covered NHGRI Disease pathway clusters for the
Joint GWAS gene list are reported in Table 5.
We provide an additional comparison to a simple method of com-
bining pathway analyses: we take the Cross and Target diseases and
performpathway analysis on them separately, then retain the pathways
enriched in both analyses. Genes occurring in retained pathways are
termed as the “Combined Target-Cross disease gene list” and are used
tomeasure pathway cluster coverage as previously described. We com-
pare the Joint GWAS gene list pathway coverage to the Combined
Target-Cross disease gene list pathway coverage in Table S5.
The false-positive rate for NHGRI Disease pathway cluster coverage
was computed using the number of genes in the Joint GWAS gene list
that were either 1) not present in an enriched pathway in the Joint
GWAS gene list or 2) not present in a pathway contained in a NHRGI
Disease pathway cluster. This quantity of genes over the size of the
Joint GWAS gene list becomes the false-positive rate for NHGRI Disease
pathway cluster coverage of the Joint GWAS gene list (Table S3).
Novel pathway association methods
For each Joint GWAS gene list, we identiﬁed the genes that did not
cover any NHGRI Disease pathway clusters, calling these the “Left-Over
gene list.” Using DAVID, we generated enriched pathways from the
Left-Over gene list. These pathways are potential novel associations
with the Target Disease, which we checked by measuring enrichment
of nominally signiﬁcant SNPs (p b 0.05) in those genes from among
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p-value b 0.05) for enrichment were then further assessed for enrich-
ment signiﬁcance by permutation test.
The permutation test was conducted as follows. To assess the signif-
icance of a pathway, we took the genes in that pathway from the Joint
GWAS gene list and then selected random sets of genes of the same
size. To select genes that had a similar chance of low p-value SNPs, the
random set was selected from among the top Ng genes from the target
GWAS, where Ng is the total number of genes in the Joint GWAS gene
list. The random set of genes was then checked for the number of low-
p-value SNPs, those meeting a nominal cut off of 0.05 for association
in the Target GWAS. The total number of such SNPs was compared to
the expected number of such SNPs using Chi-square or Fisher's exact
tests. Since the Target GWASwas already ﬁltered for linkage disequilib-
rium down to SNPs with no more than r2 = 0.3, linkage disequilibrium
was not an important factor in this permutation testing scheme. For
each pathway, 1000 such random sets were generated and measured
to get an estimate of the null distribution. Pathways with Chi-square
or Fisher's exact p-values that were lower than all 1000 of the random
values were considered enriched for Target Disease GWAS SNPs.
Pathways enriched for Target Disease GWAS SNPs were considered
to be potential novel ﬁndings. These pathways may represent 1) novel
biological associations to the target disease, 2) biological ﬁndings truly
associated with this disease, and known to be so, but not previously
associated with the Target Disease through a GWAS, and therefore
unknown to the NHGRI GWAS catalog, or 3) false-positive results. We
identiﬁed pathways matching case (2) by conducting PubMed queries
containing the conjunction of the Target Disease name and a concise
pathway descriptor (Table 6). In some cases, synonymous search
terms were used for unusual pathway descriptors, which are indicated
by vertical grouping in Table 6.
All analysis was conducted with MATLAB and Perl code written by
the authors. Software available by request.
Null simulation methods
To provide a controlled test of the Joint GWAS Association method-
ology, we constructed a series of null GWAS that have no biological
phenotype. We also constructed a series of Vascular Endothelial Growth
Factor (VEGF) Pathway-enhanced GWAS by taking the null GWAS and
inserting inﬂated effect sizes for SNPs appearing in genes appearing in
the BioCarta VEGF, Hypoxia, and Angiogenesis pathway (www.BioCarta.
com). We generated 20 null-Joint GWAS Analyses by taking the WTCCC
controls and randomly splitting them into four groups: cases for Null Tar-
get GWAS, controls for Null Target GWAS, cases for Null Cross GWAS, and
controls for Null Cross GWAS. For each of these 20 random splits, we then
performed twoGWAS (the Null Target GWAS, and the Null Cross GWAS),
and then performed Joint GWAS Analysis on these two GWAS. For each
Null GWAS, we obtained VEGF pathway-enhanced GWAS by using the
GCTA software [44] to simulate effect sizes of VEGF pathway SNPs,
which we then inserted into the Null GWAS. We then performed Joint
GWAS Analysis on 20 pairs of VEGF GWAS.We compare results between
Joint GWASAnalysis of Null and of VEGF GWAS (see Supplementalmate-
rial, Tables S7, S8 and S9).
Results
Using simple case–control designs, we conducted GWAS of each
of the six diseases. We obtained similar results to the original WTCCC
GWAS (2007). For each pair of the six diseases, we applied Joint
GWAS Analysis (see Methods). In each Joint GWAS Analysis, the maxi-
mum enrichment occurred when considering the top 12% to 24% of
SNPs (Fig. 2, Table 1). We found the strongest enrichment between
rheumatoid arthritis and type 1 diabetes (Fig. 2), although this did not
result in the most Common SNPs selected (Row “M”, Table 1). The gen-
eral character of the enrichment for each Joint GWAS pair, as M wentfrom 1 to approximately 100,000, showed marked similarity (Fig. 2). A
simulation of 20 null GWAS showed less enrichment than each of the
WTCCC Joint GWAS. At each of the SNP, Gene, and Pathway levels we
assessed the extent to which the Joint GWAS SNP list revealed known
associations to the Target Disease. Known associations are derived
from the NHGRI GWAS catalog [16], a reference that includes all
published SNP and gene associations for any trait or disease from stud-
ies that survey at least 100 k SNPs and that meet a p b 10−5 statistical
signiﬁcance threshold.
SNP, gene, and gene-cluster levels
For each Joint GWAS, we compared the Joint GWAS SNP list with the
Target GWAS SNP list on their overlapwith SNPs identiﬁed in theNHGRI
GWAS catalog for the Target Disease. Our general method proceeds as
follows (Figure S1). We wished to know if Joint GWAS Analysis is able
to identify true disease SNPs, and how Joint analysis compares to Target
GWAS testing alone. We therefore compared the Joint GWAS SNP list to
the NHGRI Disease SNP list for that disease. Results, in Table 2, show that
both the Joint GWAS SNP list and the Target Disease SNP list identify
some of the SNPs that have been associated with the six diseases in
previously published GWAS, with the Joint GWAS method identifying
less SNPs in all cases than the Target Disease alone. Joint GWAS Analysis
identiﬁed many SNPs (Nsnp = ~3000 to ~6000, Table 1) as potentially
associated with the Target Disease, which leads to large false-positive
rates (~99.9%) at the SNP-level; a result to be expected by including so
many top SNPs, and one mirrored in the Target GWAS SNP list. Similar
results are seen at the gene level (Table 3), with false-positive rates in
Table S1; although in some cases the Joint GWAS gene list identiﬁed
more NHGRI disease genes than the Target gene list, in particular Joint
GWAS Analyses using CAD as the Cross Disease. We also note that the
Joint gene and Target gene lists did not merely identify the same
genes from the NHGRI database, but in most cases the Joint gene list
provided additional genes not identiﬁed by the Target gene list alone
(Table S3).
To assesswhether the genes overlapped in function rather than just in
name, we used the DAVID pathway enrichment online tool to obtain
functional groupings [19] for the genes in the Joint GWAS, Target
GWAS, and NHGRI Disease gene lists. This use of the DAVID tool clusters
genes into groups based on similar function (in contrast to clustering
biological pathways into groups based on redundant genes, as employed
below). We counted the number of genes from the NHGRI Disease gene
list that were mapped to functional gene groups containing one of the
genes from the Joint GWAS gene list, and the Target GWAS gene list
(see Methods). Results (Table 4) show more pairs of diseases where
the Joint GeneAnalysis provides a clear improvement over just the Target
GWAS, when considered against the results from the SNP- and Gene-
level. When CAD is the Target Disease, Joint GWAS has signiﬁcantly
lower false-positive rates than the Target GWAS (Table S3). Additionally,
in almost all cases, the Joint GWAS gene clusters identify some addition-
al NHGRI disease genes that were not identiﬁed by the Target gene list
clusters (Table S4). Simulation with null and VEGF-enhanced Joint
GWAS shows that Joint GWAS Analysis identiﬁes signiﬁcantly more
VEGF-pathway genes at both the Gene level and at the Gene Functional
Group level, while having a smaller false-positive rate (Table S8).
Pathway level
Given our lists of genes, we used the DAVID biological pathway
aggregator to identify enriched pathways. These pathways are then
grouped into similar clusters using DAVID functional annotation cluster-
ing [18]. For each pair of WTCCC GWAS, we compared the pathways
enriched in the NHGRI Disease gene list to the pathways enriched in
the Joint GWAS gene list and Target GWAS gene list. For each pair of
diseases, we compared coverage by Joint GWAS gene list to coverage
by Target GWAS gene list for each of theNHGRI Disease pathway clusters
Fig. 2.Enrichment of Common SNPs for each Joint GWASAnalysis at different values ofM.M ranges from zero to approximately 106 k, which represents all SNPs in theGWAS afterﬁltering
down to tag SNPs at linkage disequilibrium b0.3. All ﬁfteen pairs of diseases are represented. Enrichment of 20 nullmodels is shown in gray, computed using a random split of the controls
and assigned an arbitrary case/control phenotype. p-Values shown are computed using a hypergeometric distribution test. For each disease pair, themaximum enrichment is highlighted
with a circle.
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showing each individual Joint GWAS pathway cluster comparison. In
Supplemental material, we also present results comparing the pathway
clusters showing signiﬁcant coverage compared to pathway clusters cov-
ered by Combined Target-Cross disease enriched pathways (Table S5);
where in 24 of 30 Joint GWAS comparisons, the Joint GWAS method
identiﬁes additional pathway clusters relative to the Combined Target-
Cross disease gene lists.
In over half of the Joint GWAS comparisons (16 of 30), there was at
least one additional pathway cluster identiﬁed with signiﬁcantly greater
gene representation in the Joint GWAS gene list over the Target GWAS
gene list (Table 5). T2D in particular had one or two additional pathway
clusters showing signiﬁcantly better coverage by the Joint gene list in all
but one Cross Disease. Interestingly, the individual pathway that was
most often signiﬁcantly increased in coverage was the “carbohydrates
and glucose homeostasis” metabolic pathway (Tables S31, S32, S33),
which seems particularly germane to diabetes etiology. In our nullTable 1
General enrichment characteristics for each Joint GWAS Analysis. Enrichment levels are chosen by
imizes that enrichment. Joint GWAS SNPs refers to the number of common SNPs in the two GWA
GWAS SNPs by using HG18. Joint GWAS Pathways are computed from genes by using the DAVID
BD vs
CAD
BD vs
CD
BD vs
RA
BD vs
T1D
BD vs
T2D
CAD vs
CD
CAD
RA
Shared tag SNPs 105,881 105,835 106,622 105,933 105,889 10,5903 106,
M 13,439 15,041 15,348 14,182 19,823 25,246 14,
Joint GWAS SNPs, Nsnp 2791 3315 3423 3185 5186 7711 3
Joint GWAS genes, Ng 690 755 669 737 684 591
Joint GWAS pathways 450 556 520 507 395 288GWAS vs. VEGF-pathway GWAS, we identiﬁed on average 1 (of 3) possi-
ble VEGF pathway clusters with signiﬁcantly greater coverage compared
to null Joint GWAS (Table S9).
To assess the degree to which genes identiﬁed by Joint GWAS gene
lists could represent novel biological ﬁndings, we took the Left-Over
gene lists in each Joint GWASAnalysis and identiﬁed enriched pathways
(see Methods). We looked for conﬁrmation outside the NHGRI catalog
that these pathways represent known associations with the Target
Disease by using PubMed searches (Table 6). We see several cases of
pathways with a large number of joint occurrences in the PubMed liter-
ature, that we consider to be instances of a pathway truly associated
with the Target Disease, although a pathway that was not indicated by
the NHGRI catalog of GWAS associations for the Target Disease. These
demonstrate that this method does correctly identify known pathways
associated with the Target Disease. There are also many cases of no co-
occurrences of the pathway and the Target Disease; these are either
cases of novel biological associations that may be validated in futurepeak signiﬁcance of common SNP enrichment (see Fig. 2).M is the number of SNPs thatmax-
S occurring prior to the peak signiﬁcance point. Joint GWAS genes are computed from Joint
pathway enrichment tool, including all pathways with enrichment scores better than 0.05.
vs CAD vs
T1D
CAD vs
T2D
CD vs
RA
CD vs
T1D
CD vs
T2D
RA vs
T1D
RA vs
T2D
T1D vs
T2D
722 106,015 105,957 106,772 105,974 105,913 106,773 106,698 106,005
233 16,175 16,638 17,121 14,721 22,039 16,093 16,716 18,518
160 3915 4121 3963 3278 6113 3926 3950 4800
755 1133 716 633 762 678 693 694 706
524 626 489 547 562 472 516 507 432
Table 2
Comparison of Joint GWAS SNP list vs. Target GWAS SNP list. For each of the sixWTCCC diseases, this table shows the number of SNPs identiﬁed by all published GWAS of that disease and
indexed in the NHGRI catalog. For eachWTCCC disease, we compare the number of NHGRI SNPs identiﬁed in the Joint GWAS SNP list (leading the slash) to the number identiﬁed in the
Target GWAS SNP list (trailing the slash). SNPswithin linkage disequilibrium of r2 ≥ 0.3 are considered representative of the SNP in question from theNHGRI list. In parentheses, we show
howmanymore NHGRI SNPswere identiﬁed by the Joint GWAS SNP list than by the Target GWAS SNP list, as a percent of the total number of NHGRI SNPs. Negative numbers indicate that
more NHGRI SNPs were identiﬁed by single, Top N Target GWAS than by Joint GWAS.
Target disease Cross disease (joint GWAS SNP list/target GWAS SNP list, (% gain))
Disease NHGRI SNPs BD CAD CD RA T1D T2D
BD 121 0 20/40 (−16.5%) 12/42 (−24.8%) 22/43 (−17.4%) 16/42 (−21.5%) 14/47 (−27.3%)
CAD 135 12/29 (−12.6%) 0 18/38 (−14.8%) 15/29 (−10.4%) 12/33 (−15.6%) 10/33 (−17.0%)
CD 151 19/74 (−36.4%) 17/82 (−43.0%) 0 16/77 (−40.4%) 17/74 (−37.7%) 16/81 (−43.0%)
RA 78 3/21 (−23.1%) 2/19 (−21.8%) 10/21 (−14.1%) 0 13/21 (−10.3%) 6/21 (−19.2%)
T1D 78 2/33 (−39.7%) 7/35 (−35.9%) 14/34 (−25.6%) 11/35 (−30.8%) 0 9/37 (−35.9%)
T2D 131 11/43 (−24.4%) 19/39 (−15.3%) 11/48 (−28.2%) 4/39 (−26.7%) 26/43 (−13.0%) 0
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Discussion section, below.
Discussion
Joint GWAS Analysis, even when combining seemingly unrelated
diseases, leads to signiﬁcant novel pathway association hypotheses, as
well as the identiﬁcation of additional known genes and pathways
associated with the Target disease. That these results were the conse-
quence of combining GWAS of disparate complex genetic disorders
indicates that these diseases share genomic etiology to some extent.
Consider the opinion of Wang et al.: “…joint analysis of related GWA
study data sets may help reveal shared susceptibility pathways in a
more powerful manner. This would be particularly relevant for diseases
for which the genetic overlap is not well-understood.”[41] Our Joint
GWAS Analysis method achieves this, by demonstrating that meta-
analysis of GWAS need not be restricted to GWAS of the same disease.
While Joint GWAS Analysis has provided encouraging results, as
presented it has some limitations, andby addressing these it is our belief
that greater genomic understandingwill be forthcoming. Ourmethod is
dependent upon the constituent GWASes and their execution: these
must account for appropriate covariates, environmental factors, and
stratiﬁcation in order to provide the best input for Joint GWAS Analysis.
Similarly, since we rely on GWAS data, we do not consider other forms
of genomic data and variation, such as copy number variation, rare
variants, gene expression, or gene epigenetics; although in principal
these could be included in future versions of our methodology. In an
effort to make our results as relevant as possible, we endeavored to
mimic the original WTCCC GWASes as much as possible, including
methods of population stratiﬁcation control. We also experimented
with including the top six genotype principal components as covariates,
and found this resulted in somedifferences in the SNPs, genes, and path-
ways identiﬁed (+/−20% in some cases), although the character of our
results was largely unchanged. In general, we would need to perform
Joint GWAS Analysis on many more pairs of GWAS to get a goodTable 3
Comparison of Joint GWAS gene list vs. Target GWAS gene list. For each of the sixWTCCC disea
and indexed in theNHGRI catalog. For eachWTCCC disease, we compare the number of NHGRI g
the Target GWAS gene list (trailing the slash). In parentheses, we show howmanymore NHGR
percent of the total number of NHGRI genes. Negative numbers indicate that more NHGRI gen
Target disease Cross disease (joint GWAS gene list/target GWA
Disease NHGRI genes (n) BD CAD CD
BD 130 0 8/6 (1.5%) 8/
CAD 92 6/7 (−1.1%) 0 5/
CD 203 9/7 (1.0%) 5/5 (0.0%) 0
RA 66 5/6 (−1.5%) 8/5 (4.5%) 6/
T1D 61 4/3 (1.6%) 7/4 (4.9%) 7/
T2D 105 13/14 (−1.0%) 17/12 (4.8%) 12understanding of what types of diseases would bemost fruitful to com-
bine, andwhich covariates aremost important to include.We could em-
ploy alternativemethods of assigning SNPs to genes, or of ranking genes
by the p-values of their SNPs, of which there has been much recent dis-
cussion in the literature. The list of NHGRI Disease pathways identiﬁed
from the NHGRI GWAS gene list can be considered a partial summary
of the known biology of the Target Disease; not a perfect representation,
but at least a summary of what has been established through GWAS.
Since Joint GWAS Analysis starts with only GWAS, the NHGRI GWAS
catalog makes a ﬁtting benchmark for what is achievable through
GWAS meta-analysis. On the other hand, our Joint GWAS methodology
has the desirable beneﬁt that it is not limited to GWAS that were
performed on the same cohorts or with the same gene chip. In fact,
the core of the method merely needs the ordering of SNPs by signiﬁ-
cance, and so does not require the original genotyping data at all. This
can be an important factor in performing GWAS meta-analyses of
potentially sensitive patient genomic data. Given a list of genes, there
are many popular methods for determining enrichment of various
biological categories or pathways.[17] The DAVID web tool aggregates
pathway databases from a number of other pathway providers or
categories: Gene Ontology (GO), GO Molecular Function, GO Cellular
Component, KEGG Pathways, BioCarta Pathways, Swiss-Prot Keywords,
BBID Pathways, SMART Domains, NIH Genetic Association DB, UniProt
Sequence Features, COD/JOG Ontology, NCBI OMIM, InterPro Domains,
PIR Super-Family Names, and Biological Processes.[19] In order to avoid
a bias incurred by using one pathway provider exclusively (e.g., limiting
ourselves to only GO or only KEGG), we used the pathways identiﬁed as
enriched by DAVID, however the results presented herein are still sensi-
tive to the pathway tool we chose to use; in principal any biological path-
way aggregator could be used. In our current analysis, results may vary
based on the parameters used inDAVID searches, including the particular
pathway providers included in the aggregation and the signiﬁcance
thresholds used to identify signiﬁcant pathways or pathway clusters. As
our analysis of the VEGF and Null models shows, some genes may be
undetectable through our method if they are too small to contain tagses, this table shows the number of genes identiﬁed by all published GWAS of that disease
enes identiﬁed by the Joint GWAS gene list (leading the slash) to the number identiﬁed by
I genes were identiﬁed by the Joint GWAS gene list than by the Target GWAS gene list, as a
es were identiﬁed by single, Target Disease GWAS than by Joint GWAS.
S gene list, (% gain))
RA T1D T2D
6 (1.5%) 4/6 (−1.5%) 7/6 (0.8%) 4/6 (−1.5%)
12 (−7.6%) 7/12 (−5.4%) 13/13 (0.0%) 6/12 (−6.5%)
10/17 (−3.4%) 13/20 (−3.4%) 11/18 (−3.4%)
7 (−1.5%) 0 6/11 (−7.6%) 6/11 (−7.6%)
7 (0.0%) 5/7 (−3.3%) 0 2/12 (−16.4%)
/14 (−1.9%) 14/11 (2.9%) 15/17 (−1.9%) 0
Table 4
Comparisonof JointGWASgene list vs. TargetGWASgene list, considering functional overlap ofNHGRI genes. For eachof the sixWTCCCdiseases, this table shows thenumber of genes identiﬁed
by all published GWAS of that disease and indexed in the NHGRI catalog. For eachWTCCC disease, we compare the number of NHGRI genes mapped to a functional category including a gene
from JointGWASgene list (leading the slash) to thenumber identiﬁed to thenumbermapped to a functional category including a gene from theby the TargetGWASgene list (trailing the slash).
This shows the difference in identiﬁed functional gene clusters for each pair of diseases using the Joint GWAS method and the identiﬁed functional gene clusters for each Target Disease
considered singly. In parentheses, we show howmany more NHGRI genes were identiﬁed by the functional categories of Joint GWAS genes than by single, Target GWAS genes, as a percent
of the total number of NHGRI genes. Results are dependent upon DAVID parameters (signiﬁcant thresholds, pathway providers included in the aggregation). (*) indicates Joint GWAS gene lists
that resulted in signiﬁcantly lower false-positive rates than Target GWAS gene lists; signiﬁcance assessed by Chi-square test (or Fisher's exact test in cases of low sample size).
Target disease Cross disease (joint GWAS gene list/target GWAS gene list, (% gain))
Disease NHGRI genes (n) BD CAD CD RA T1D T2D
BD 130 0 77/79 (−1.5%) 79/83 (−3.1%) 80/80 (0.0%) 76/84 (−6.2%) 69/80 (−8.5%)
CAD 92 42/36 (6.5%) 0 45/45 (0.0%) 47/44 (3.3%) 49/58 (−9.8%) 46/43 (3.3%)
CD 203 121/122 (−0.5%) 112/97 (7.4%) 0 110/132 (−10.8%) 114/136 (−10.8%) 132/134 (−1.0%)
RA 66 41/44 (−4.5%) 44/48 (−6.1%) 42/40 (3.0%) 0 39/48 (−13.6%) 44/48 (−6.1%)
T1D 61 35/33 (3.3%) 35/36 (−1.6%) 35/36 (−1.6%) 34/36 (−3.3%) 0 30/35 (−8.2%)
T2D 105 67/61 (5.7%) 66/58 (7.6%) 64/69 (−4.8%) 67/69 (−1.9%) 68/64 (3.8%) 0
208 M.J. McGeachie et al. / Genomics Data 2 (2014) 202–211SNPs (see Table S8); a weakness related to the necessity of pruning the
GWAS fairly stringently for linkage disequilibrium. Thismay result in cer-
tain pathways being hard to detect as enriched, or very large genes being
much easier to detect. In futurework, wewill consider differentmethods
for accounting for LD between SNPs and preserving tag SNPs for small
genes.
A study of complex disease similarity at four different genomic reso-
lutions was undertaken previously in the WTCCC GWASes by Huang
et al.[20] They compared WTCCC GWASes at the SNP, gene, protein,
and phenotype level, concluding that CD, RA and T1D have overlap at
all four levels, while CAD, T2D, and hypertension do not exhibit similar-
ity despite being commonly considered to be phenotypically similar.
The similarity of WTCCC GWASes was also examined by Torkamani
et al., who measured the correlation between gene p-values associated
with each disease [38]. These authors found considerable similarity
between BD, CAD, and T2D (in contrast to ﬁndings of Huang et al.,
above). Importantly, Torkamani et al. considered the possibility that
the similarity exhibited by WTCCC GWASes might be due to WTCCC's
use of a common set of control patients for each disease cohort. They
proceeded to conduct a number of simulations that ruled out this possi-
bility, stating that the similarities observed “…are not an artifact arising
from WTCCC's use of common controls” for each GWAS [38]. Our Joint
GWAS Analysis builds on this tradition of identifying genetic similarity
in WTCCC cohorts, and goes further by leveraging this similarity to
gain biological insight into each of the six diseases separately.
Methods for associating SNPs with multiple related traits have been
recently reviewed [31]. The broader pursuit of examining multiple
GWAS phenotypes has been explored in various ways, with some
authors proposing combining traits before performing the GWAS as a
way to increase power to detect pleiotropic genes [25]. Others have
usedmultiple GWAS of the same disease to enhance biological pathway
analysis [21], and statistics have been developed to identify pleiotropic
SNPs from among several GWAS of related traits [7]. Our work builds
on these ideas but explores a somewhat different question: that ofTable 5
Comparison of Joint GWAS gene list pathway coverage vs. Target GWAS gene list pathway cov
signiﬁcantly increased coverage by genes in enriched pathways from the Joint GWAS gene list.
tiﬁedwith greater coverage than obtained by the Target gene list. Results are dependent upon D
Target disease Cross disease (joint
Disease NHGRI pathway clusters (n) BD C
BD 6 – 1
CAD 12 0 –
CD 9 1 0
RA 5 0 0
T1D 3 0 0
T2D 9 2 1using multiple GWAS of different phenotypes to enhance understand-
ing of a single trait. Furthermore, it has been observed that existing
methods of investigating gene pleiotropy will result in underestimates
by missing SNPs with only moderate GWAS associations [35], an effect
that our method addresses by virtue of its methodological similarity
with pathway analysis: investigating a large proportion of the top
GWAS SNPs while minimizing the multiple comparison problem.
The idea of considering the enrichment of gene sets has a richhistory
going back to Mootha et al.,[24] although these methods are less
frequently employed in SNP comparisons, as employed in our Joint
GWAS Analysis. Our method nevertheless owes much to these earlier
gene set enrichment methods, particularly Subramanian et al.,[37]
who considered the “leading edge” genes to be those that increased
the enrichment score, and served a similar function to our maximum
enrichment cut point (M, in Fig. 1). Also, other researchers have
proposed methods of comparing lists of genes [9,24,45], however
these have not been applied to lists of SNPs in the manner employed
by our Joint GWAS methodology.
Where we have used DAVID pathway clusters, other researchers
have used othermethods of grouping pathways or pathway constituents
[21]. Any such grouping of pathways is necessary to avoid problemswith
individual pathways, including: incomplete functional descriptions pro-
vided by ontologies such as GO [34]; enrichment results varying widely
across different enrichment tools [9]; ontology inconsistencies that
make counting or comparing between pathways difﬁcult — redundant
pathways, uneven hierarchical structures, and terms of varying sizes or
memberships.
As might be expected for a pathway-based methodology, the results
at the SNP-level were not encouraging for Joint GWAS Analysis: with
the Target GWAS SNP list identifying many more known disease-
associated SNPs. However, the picture improved as the analysis moved
to broader scopes, to genes, to gene functional-clusters, and to pathways.
There are many cases of the Joint gene list identifying more disease-
associated genes than the Target gene list (Table 3); in particular inerage. For eachWTCCC disease, we compare the number of NHGRI pathway clusters with
Zeros do not necessarily indicate no pathways identiﬁed, just that no pathways were iden-
AVID parameters (signiﬁcant thresholds, pathway providers included in the aggregation).
GWAS pathway coverage in excess of target GWAS pathway coverage)
AD CD RA T1D T2D
0 1 0 0
1 0 1 0
– 2 0 2
1 – 0 1
1 1 – 1
1 0 2 0
Table 6
Novel GWAS pathways identiﬁed for eachWTCCC diseasewith PubMed citations returned for the conjunction of pathway and disease search terms. Highlighted cells indicate pathwayswhere
wehypothesize an association of thepathway to thedisease. Other cells are included for completeness, althoughnohypothesiswas indicated. Greenhighlights indicate pathwayswhere there is
evidence in the literature for an association with the WTCCC disease, pink indicates pathways where there does not seem to be evidence of a known association; orange shading indicates
pathways where there is indeterminate evidence for an association. Pathway names are summarizations generated by hand, by the authors, where pathway names in grouped rows are syn-
onyms used for PubMed searches. Search terms in quotes were quoted in their submission to PubMed andwere required to appear exactly in that order in the abstracts or titles of the research
articles in question. Search terms grouped horizontally represent synonymous search terms that were used to get a broader picture of the relationship of the pathway to the six diseases.
Pathway (None) BD CAD CD RA T1D T2D
(None) 35517 1858254 37755 117204 63862 97706
Axoneme 1551 0 38 0 0 0 0
Organelle 408230 124 14129 155 805 406 1301
Transcription regulator 30645 14 687 34 101 74 197
Transcription regulation 210704 126 5588 208 788 353 1044
"Zinc finger" 11743 14 231 6 30 10 26
Zinc-binding 2985 0 27 4 9 3 4
"RNA processing" 10018 5 115 1 11 2 8
Deaminase 15088 14 503 7 118 19 106
Hydrolase 1099984 605 78923 1047 5347 2663 4793
Chromosomal part 69229 41 1652 17 180 51 91
Telomere 15003 16 577 4 38 21 64
Centromere 11780 12 356 5 124 9 3
RNA-binding 26160 10 283 6 50 16 71
RNA polymerase ii 25301 14 967 26 102 40 84
"RNA polymerase ii" 10244 1 81 0 9 4 8
Cytoskeleton 93580 35 3067 23 125 38 94
"Cell cycle" 144054 38 3274 49 261 79 232
Amino acid biosynthesis 782401 637 25466 357 1881 1317 2729
"Amino acid biosynthesis" 918 0 3 1 0 0 1
"Amino acid synthesis" 417 0 2 0 0 2 2
Paraneoplastic 
Encephalomyelitis 4274 6 213 2 55 11 2
Pleckstrin homology 2028 1 16 0 3 0 8
GTPase activating 9456 6 207 5 9 10 40
"GTPase activating" 6102 3 122 3 5 7 29
Phosphorylation 217206 150 9632 126 609 330 1953
Magnesium 88802 118 6245 80 101 173 340
"Magnesium ion" 1299 1 50 0 2 0 2
"Magnesium ion binding" 37 0 0 0 0 0 0
Nuclear lumen 1231 0 152 6 0 0 4
"Nuclear lumen" 10 0 0 0 0 0 0
Nucleoplasm 2261 0 21 0 8 0 1
"Purine metabolism" 1421 1 101 1 15 3 8
"Purine binding" 97 0 1 0 0 0 0
Purine 448484 282 29579 1269 1532 611 1513
Ubiquitin 37124 14 1123 34 89 66 98
Ubiquitin-associated 254 0 0 0 1 0 0
Key: Known Unknown Partial
209M.J. McGeachie et al. / Genomics Data 2 (2014) 202–211cases of CAD as the cross disease. At the level of gene functional clusters
(Table 4) there aremore cases of improved performance in the Joint gene
list than therewere at the gene-level. Althoughwewould expect diseases
to appear to be more similar as we considered broader categories of
genomic resolution, we should have no similar expectation of the JointGWAS analysis out-performing single GWAS – this occurrence is an im-
portant result. At the pathway-cluster genomic resolution, we see that
there is a further increase in the number of disease pairs that show a ben-
eﬁt of the Joint GWAS methodology over single GWAS (Table 5). There
are 17 disease pairs showing statistically increased coverage of 1 or 2
210 M.J. McGeachie et al. / Genomics Data 2 (2014) 202–211pathway clusters by the Joint GWAS method than by the Target GWAS.
These results are particularly concentrated in the pathway clusters of
T2D, which may be reﬂective of the broad metabolic basis of the disease
leading to a diffuse genetic etiology. Our simple simulation of null vs.
VEGF-pathway-enhanced Joint GWAS indicates that Joint GWAS Analysis
does indeed identify pathways common to two GWAS, when those
pathways are enriched for low-p-value GWAS SNPs. This general
success of Joint GWAS Analysis at the pathway level demonstrates
its ability to identify additional relevant biology, surpassing that
which is identiﬁable from the single GWAS alone. This is also true
to a lesser extent at the gene-cluster level (Table S4) and gene-
level (Table S3), where genes missed by the Target GWAS are
found by the Joint GWAS, although to a lesser extent in Target dis-
eases RA and T1D (Table S4). In fact, RA and T1D may be the poor
choices for Joint GWAS Analysis, since they have a large portion of
their genetic basis localized to the MHC region of chromosome 6.
These two are not broad-based, multi-genic disorders on the same
scale as BD, T2D, CD, and CAD.
When using Joint GWAS Analysis to identify novel biological associ-
ations, we used the Left Over genes from the pathway-level analysis
to generate candidate pathways associated with the Target Disease
(Table 6). That several of the hypothesized pathway associations
already have great support in the PubMed literature suggest that
many of these hypotheses are truly associated with the Target Disease
(see Table S6 for representative references).While each of these catego-
ries represents a group of proteins, some of which have known associa-
tions to Target Diseases (cells highlighted in green in Table 6), many do
not have published associations with the Target Disease yet (cells
highlighted in pink in Table 6). To look for novel biological hypotheses,
we looked at the pathwayswithout current PubMed literaturematches:
axoneme-related proteins in BD; RNA polymerase II dysfunction in RA,
amino acid synthesis pathways in RA, and paraneoplastic encephalomy-
elitis in RA; and proteins containing Pleckstrin homologue domains in
T1D, magnesium ion binding proteins in T1D, and nuclear membrane
related proteins in T1D. Of these, paraneoplastic encephalomyelitis
refers to an inﬂammatory disease thatmay share immune-related caus-
ative genes with RA, and may therefore not lead to new avenues of
research; magnesium ion binding proteins may refer to RNA or ATP,
this may actually be too broad to be of scientiﬁc use. Others of these
make for very interesting hypotheses: RNA polymerase II association
with rheumatoid arthritis, and axoneme proteins in bipolar disorder.
These are, in our estimation, the most promising candidates for novel
biological association generated by Joint GWAS Analysis.
Our results invoke the general pleiotropy of disease-causing genes
and biological systems, and the general relatedness of complex disor-
ders, as described, for example, by Barabasi et al. [3] Pleiotropy is
becoming more evident as more genomic regions are associated with
more conditions. A study of autoimmune disorders found many SNPs
were involved withmore than one disease, and this lead to new associ-
ations between genomic loci and some diseases [29]. In the WTCCC
GWAS themselves, BD, T2D, and CADwere found to have slight positive
correlations among their top SNPs [32]. Furthermore, the related-
ness of complex disorders is evident in clinical settings, where com-
plex diseases show signiﬁcant comorbidity [4], and in patients over
65 years of age, it is common to observe more than 10 related dis-
eases [27]. Another study looked at the co-occurrence of 161 dis-
eases in 1.5 million clinical patients, and found a strong correlation
between incidence of BD and of T2D, T1D, and RA, among others
[30]. The same study found strong correlations between T2D and
T1D, BD, and RA [30]. While many pleiotropy studies focus on the
family of autoimmune diseases, a recent study identiﬁed seven
genes with pleiotropic effects across cardiovascular- or metabolic
syndrome-related conditions [13]. Others have observed that genes
associated with complex disorders tend to be interconnected in
interaction networks [5]. Our present work can be seen as an exten-
sion of these results.Acknowledgments
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by P01-HL083069 and U01-HL065899.Appendix A. Glossary of deﬁned terms
Joint GWAS Analysis. Our method of combining two GWASes of
different disorders for the purpose of gaining information about each
disease individually.
Target disease. One of two diseases considered in the two GWAS of a
Joint GWAS Analysis. For pedagogical purposes, we designate one of the
two the Target Disease, and measure how much of known associations
to the Target Disease are recovered in Joint GWAS Analysis.
Target GWAS. The GWAS of the Target Disease.
Cross disease. The other of the two diseases considered in the
two GWAS of a Joint GWAS Analysis. For pedagogical purposes, we
designate one of the two the Target Disease and the other the
Cross Disease.
Cross GWAS. The GWAS of the Cross Disease.
Joint GWAS SNP list. In a Joint GWASAnalysis, the list of SNPs obtained
by crossing the Target and Joint GWAS and selecting the common SNPs
from among the top M ranked SNPs.
Joint GWAS gene list. In a Joint GWAS Analysis, the list of genes
obtained by translating the Joint GWAS SNP list into genes using a
genomic map (e.g., HG18).
Target GWAS SNP list. In a Joint GWAS Analysis, the list of SNPs
obtained by taking the top Nsnp SNPs from the Target GWAS, where
Nsnp is the size of the Joint GWAS SNP list.
Target GWAS gene list. In a Joint GWAS Analysis, the list of genes
obtained by translating enough of the top SNPs from the Target GWAS
SNP list into genes, in order to obtain Ng unique genes, where Ng is
the size of the Joint GWAS gene list.
NHGRI disease SNP list. A list of SNPs associated with the Target
Disease in any GWAS listed in the NHGRI GWAS catalog conducted on
the Target Disease.
NHGRI disease gene list. A list of genes associated with the Target
Disease in any GWAS listed in the NHGRI GWAS catalog conducted on
the Target Disease.
NHGRI disease pathway clusters. A list of pathway clusters identiﬁed
as enriched by the DAVID pathway aggregator tool, upon the input of
the NHGRI Disease gene list.
M. In a Joint GWAS Analysis, the number of SNPs maximizing the
enrichment p-value for common SNPs between the Cross GWAS and
Target GWAS.
Nsnp. The size of the Joint GWAS SNP list.
Ng. The size of the Joint GWAS gene list.
Common SNPs. In a Joint GWAS Analysis, the SNPs occurring in
both the top M SNPs of the Target GWAS and the Cross GWAS, for
any value of M.
Covered. The genes (or the number of genes) from either the Joint
GWAS gene list or Target GWAS gene list that occur in an enriched
pathway of that list, and that occur in an NHGRI Disease pathway
cluster.
Left-over gene list. List of genes obtained from the Joint GWAS gene
list that did not cover any NHGRI Disease pathway clusters.Appendix B. Supplementary data
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.gdata.2014.04.004.
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